针对炎症和氧化应激,以改善TNBS小鼠克罗恩结肠炎模型的结果
Anisha Apte1, James R Bardill2, Jimena Canchis1
1Laboratory for Fetal and Regenerative Biology, Department of Surgery, University of Arizona Tucson College of Medicine, Banner Children's at Diamond Children's Medical Center, Tucson, AZ 85721, USA.
Nanomaterials (Basel, Switzerland)
|May 24, 2024
概括
与microRNA 146a (CNP-miR146a) 结合的氧化纳米粒子减少了克罗恩病小鼠模型中的炎症和氧化应激. 这种新型化合物改善了临床结果,并降低了结肠炎的炎症标志物.
科学领域:
- 生物医学工程 生物医学工程
- 纳米医学是一种纳米医学.
- 胃肠病学 胃肠病学
背景情况:
- 克罗恩氏病的发病包括炎症和氧化应激.
- 微RNA 146a (miR146a) 在调节炎症反应方面发挥作用.
- 氧化纳米粒子 (CNPs) 具有抗炎和抗氧化特性.
研究的目的:
- 在克罗恩病小鼠模型中研究CNP-miR146a的治疗潜力.
- 评估局部CNP-miR146a在减少结肠炎症方面的疗效.
主要方法:
- 在Balb/c小鼠中使用2,4,6-Trinitrobenzenesulfonic acid (TNBS) 浸泡剂诱导大肠炎.
- 通过阴囊进行局部注射CNP-miR146a.
- 评估临床疾病活性,体重减轻,结肠组织学,miR146a表达和炎症性细胞因子 (IL-6,TNF) 水平.
主要成果:
- CNP-miR146a淋巴瘤增加了结肠中的miR146a表达.
- 接受治疗的小鼠减轻了体重减轻和改善了组织学炎症评分.
- 观察到IL-6和TNF基因表达和蛋白质度显著降低.
结论:
- 局部输送的CNP-miR146a有效地改善了急性实验性结肠炎.
- 通过减少炎症信号,CNP-miR146a显示出作为克罗恩病治疗剂的潜力.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115


